Session » Epidemiology and Public Health - Poster I

Date: Sunday, November 13, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 27

A Rheumatologist’s Assessment of Therapy Responses (Rxresp) and Rheumatoid Factor Status (neg/pos) in 1995 Predicted Mortality through 2015 in a Community-Based Cohort of Incident Rheumatoid Arthritis Cases and Matched Control Subjects

9:00AM-11:00AM: Abstract Number: 15

Adverse Events and Persistency of Biologics in Rheumatoid Arthritis Patients with Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 28

Baseline Serum Inflammatory Biomarkers at Cohort Entry in 1974 Predicted Cardiovascular Disease (CVD) Mortality from 1995 through 2015 in a Prospective, Community-Based Study of Incident Rheumatoid Arthritis (RA) Patients and Matched Non-RA (CN) Subjects

9:00AM-11:00AM: Abstract Number: 12

Benefit of Early Therapy with Methotrexate and Prednisone in Patients with Early Rheumatoid Arthritis and Undifferentiated Early Arthritis (CONAART)

9:00AM-11:00AM: Abstract Number: 20

Diabetes and Other Comorbidities in Rheumatoid Arthritis Patients Starting a Biologic DMARD: A Multi-Database Cohort Study

9:00AM-11:00AM: Abstract Number: 16

Differences Between Patient and Physician Global Assessment on Rheumatoid Arthritis Disease Activity Status in High and Lower Income Countries Contribute to Inequity

9:00AM-11:00AM: Abstract Number: 11

Drug Prescribing Trends in Adults with Rheumatoid Arthritis: A Population-Based Comparative Study from 2005-2014

9:00AM-11:00AM: Abstract Number: 9

Effects of Alcohol Consumption on the Severity of Inflammation in Hand and Foot Joints Detected with MR Imaging

9:00AM-11:00AM: Abstract Number: 1

Factors Predicting Likelihood of Remaining Positive for Rheumatoid Arthritis-Related Autoantibodies Following Autoantibody Screening

9:00AM-11:00AM: Abstract Number: 14

Failure Predictors to Anti-Tumor Necrosis Antagonists in Patients with Chronic Arthritis: Results of a National Registry Biobadasar

9:00AM-11:00AM: Abstract Number: 13

Genetic Variants of the Vasoactive Intestinal Peptide (VIP) Gen in Association with Rheumatoid Arthritis Treatment Requirements

9:00AM-11:00AM: Abstract Number: 25

Have Outcomes of Patients with Inflammatory Arthritis Improved in the New Millennium? a Comparison of the 10 Year Outcome in Cohorts Recruited in 1990-4 and 2000-4

9:00AM-11:00AM: Abstract Number: 30

Impact of Interstitial Lung Disease on Mortality of Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 22

Incidence and Factors Associated with the Development of Non Alcoholic Fatty Liver Disease(NAFLD) Among Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 23

Incidence of Non Alcoholic Fatty Liver Disease By Key Risk Factors Among Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 7

Long-Term Dietary Changes after Rheumatoid Arthritis Diagnosis in Swedish Women: Data from a Population Based Cohort

9:00AM-11:00AM: Abstract Number: 6

Lower Omega-3 Fatty Acid Biomarkers Are Associated with Inflammatory Arthritis in a Population Positive for Anti-Citrullinated Protein Antibodies

9:00AM-11:00AM: Abstract Number: 24

Modifiable Rheumatoid Arthritis Factors and Impact on Cardiovascular Risk

9:00AM-11:00AM: Abstract Number: 21

Outcomes of Rheumatoid Arthritis Patients with Hip Fracture

9:00AM-11:00AM: Abstract Number: 31

Patients with Either Rheumatoid Arthritis (RA) or Axial Spondyloarthritis (axSpA) Self-Reported Flares in 24% of Assessments: An Observational Study of 86 Patients Assessed Weekly over 3 Months (ie, 1,100 assessments)

9:00AM-11:00AM: Abstract Number: 2

Rheumatoid Arthritis (RA)-Related Autoimmunity and Lumbar Bone Mineral Density in a Multi-Ethnic Community-Dwelling Population

9:00AM-11:00AM: Abstract Number: 4

Rheumatoid Arthritis (RA)-Related Joint Symptoms and Thoracic Bone Mineral Density in an RA-Free Community Dwelling Population

9:00AM-11:00AM: Abstract Number: 5

Rheumatoid Arthritis and Periodontitis: Association and Characteristics of Chronic Periodontitis

9:00AM-11:00AM: Abstract Number: 26

Rheumatoid Factor Positivity Increases All-Cause and Cancer Mortality Risk in Korean Healthy Examinees: A Kangbuk Samsung Health Study

9:00AM-11:00AM: Abstract Number: 29

Risk of Vascular Mortality in Seniors with New-Onset Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 18

The Impact of Disease-Related and Contextual Factors on Work Outcomes in Chronic Inflammatory Arthritis Patients Treated with Biologics: A Systematic Review

9:00AM-11:00AM: Abstract Number: 17

The Importance of Achieving Clinical Response to Treatment and Changes in Physical Ability and Quality of Life on Worker Productivity Outcomes in Rheumatoid Arthritis: Results from the British Society for Rheumatology Biologics Register

9:00AM-11:00AM: Abstract Number: 3

The Presence of Rheumatoid Factor Is Associated with Lower Bone Mass in Korean Health Screening Male Subjects without Clinically Apparent Arthritis

9:00AM-11:00AM: Abstract Number: 10

The Utility of Screening for Infectious Diseases in Recipients of Anti-TNF-α Therapy

9:00AM-11:00AM: Abstract Number: 19

Tumour Necrosis Factor Inhibition Is Associated with Weight Gain in Patients with Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 8

What Factors Relate to Patients Contributing Longitudinal Data Using Smartphone Technology? Findings from RA Patients Participating in Arthritispower Registry

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].